— IND clearance for ATR 1072 and launch of Corventis Phase 1/2 trial in PRKAG2 syndrome — — Achieved second milestone payment under global cardiovascular collaboration with Bristol Myers Squibb — SAN DIEGO, Aug. 13, 2026 /PRNewswire/ — Atrium Therapeutics, Inc. (Nasdaq: RNA)…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
